Health Trials

HS-IT101 Injection for Advanced NSCLC

ConditionAdvanced Non-Small Cell Lung Cancer
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorQingdao Sino-Cell Biomedicine Co., Ltd.

About this trial

An Open-Label, Single-Arm Phase Ib Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Efficacy of HS-IT101 Injection in Subjects with Advanced NSCLC.

Eligibility criteria

Qualifiers

Age: 18-70 years (inclusive).

Disqualifiers

Severe Hypersensitivity: History of severe hypersensitivity to drugs used in the study (including but not limited to cyclophosphamide, fludarabine, IL-2, gentamicin, amphotericin B, or components of TIL infusion).

Trial design

Treatments tested in this trial

  • Cyclophosphamide
  • Fludarabine
  • IL-2 (interleukin 2)
  • HS-IT101 monotherapy

Treatment groups

12 Participants
are divided into 1 treatment group

Sponsors and collaborators

Qingdao Sino-Cell Biomedicine Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov